Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer, Neoadjuvant Chemotherapy
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
Breast cancer is the most common malignant tumor in women. EC-TH is one of the standard chemotherapy regimens for HER-2 positive early breast cancer(EBC). Earlier use of trastuzumab may improve DFS rate.
- Trial name
- NCT04172259
- Testing
- Doxorubicin liposome, Cyclophosphamide, Trastuzumab
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Brief Summary This is an open-label, randomized, phase II clinical study designed to evaluate neoadjuvant treatment regimens in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative…
- Trial name
- NCT07492394
- Testing
- entinostat, Dalpiciclib, Letrozole
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Medical University Fourth Hospital
Breast Cancer
Dosimetric Comparison of Three Radiation Techniques for Hypofractionated Whole Breast Radiotherapy in Early Breast Cancer
We aim to compare three different radiation delivery techniques, namely three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiotherapy (IMRT) and volumetric modulated radiation therapy (VMAT) in…
- Trial name
- NCT05394194
- Volunteers
- 30 people
- Sponsor
- Sohag University
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
HER2 Positive Breast Cancer
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and…
- Trial name
- NCT03735966
- Testing
- Pyrotinib plus trastuzumab and docetaxel and carboplatin
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasm Female, Early Detection of Cancer
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women.
- Conditions
- Breast Neoplasm Female, Early Detection of Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Magnetic Resonance Imaging
- Trial name
- NCT06892275
- Testing
- Enhanced Usual Care, Decision Support
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Georgetown University
Breast Cancer, HER2 Positive
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
This study was designed to evaluate the efficacy and safety of pyrotinib combined with albumin paclitaxel and trastuzumab in the treatment of Her2-positive early or locally advanced breast cancer, and to explore RCB scores and…
- Conditions
- Breast Cancer, HER2 Positive, Combination Chemotherapy
- Trial name
- NCT04152057
- Testing
- Pyrotinib Maleate Tablets, Albumin Paclitaxel, Trastuzumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Breast Cancer
A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
A total of 340 early-stage breast cancer patients with axillary lymph node biopsy-confirmed positivity were enrolled and divided into two groups.
- Trial name
- NCT06769919
- Testing
- Neoadjuvant radiotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Xijing Hospital
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
HR+/HER2- Early Breast Cancer
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
- Trial name
- IMPACT PT (NCT07521202)
- Testing
- Standardized patient coaching
- Where
- 8 sites in Germany
- Volunteers
- 257 people
- Sponsor
- Institut fuer Frauengesundheit
Breast Cancer, Social Determinants of Health (SDOH)
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer
The overarching goal of this project is to optimize the collection of social and behavioral determinants of health (SBDOH) for patients with a pathological diagnosis of breast cancer at Penn Medicine.
- Trial name
- Breast_SBDOH (NCT06019988)
- Testing
- Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Early Gastric Cancer, Advanced Gastric Cancer
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a…
- Conditions
- Early Gastric Cancer, Advanced Gastric Cancer, Early Lung Cancer, Advanced Lung Cancer
- Trial name
- NCT07405931
- Testing
- Standardized Telenursing, Smart Cancer Care Plus
- Where
- 5 sites in South Korea
- Volunteers
- 414 people
- Sponsor
- Ulsan University Hospital
Breast Neoplasms
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
- Trial name
- NCT02771795
- Testing
- Herceptin (trastuzumab), SB3 (proposed trastuzumab biosimilar)
- Where
- 40 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 538 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Breast Cancer
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Early identification of patients at risk for cardiotoxicity represent a primary goal for cardiologist and oncologist From all adjuvant trials echocardiography is ideal for evaluating Left Ventricular function though its operator…
- Trial name
- NCT02062983
- Testing
- Herceptin
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- National Guard Health Affairs
Breast Cancer
Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence, treatment satisfaction, health-related quality of…
- Trial name
- REPOWER (NCT07243002)
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasm
FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer
The purpose of the study is: to assess the potential benefits of 18F-[FDG] PET/CT and PET/MRI for operable breast cancer in order to define the size and location of the primary tumor, as well as axillary, supraclavicular and…
- Trial name
- NCT01432002
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Geneva
Breast Cancer
Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients
This is a phase II study. In patients with node-negative invasive breast cancer or carcinoma in situ treated by breast conserving surgery, postoperative whole breast irradiation with inversely intensity modulated radiotherapy and…
- Trial name
- IMRT-SIB (NCT01394575)
- Testing
- IMRT with an simultaneous integrated boost
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Fudan University
HER2-Positive Early Breast Cancer
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
This is a Phase II, randomized, multicentre, multinational, open-label, cross-over study in adult patients who have completed neoadjuvant chemotherapy with neoadjuvant pertuzumab and trastuzumab and have undergone surgical…
- Trial name
- PHranceSCa (NCT03674112)
- Testing
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Early-Stage Breast Cancer, Neoadjuvant Therapy
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients.
- Trial name
- COGNITION (NCT05906407)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- German Cancer Research Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.